Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00529789 · ClinicalTrials.gov registry record · Phase 2
Open-Label Study of Duloxetine in the Treatment of Children and Adolescents With Major Depressive Disorder
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT00529789 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 72 participants.
The verdict
NCT00529789, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
The primary purpose of your participation in this study is to help answer the following research question, and not to provide you treatment for your condition. Whether duloxetine once daily orally is tolerated and safe, in children (aged 7 through 11 years) and adolescents (aged 12 through 17 years) with Major Depressive Disorder.
Interventions
- DRUG duloxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00529789
The ClinicalTrials.gov registry entry for NCT00529789 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which duloxetine is the first listed.
NCT00529789 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00529789 about?
NCT00529789 is a clinical study titled "Open-Label Study of Duloxetine in the Treatment of Children and Adolescents With Major Depressive Disorder". The primary purpose of your participation in this study is to help answer the following research question, and not to provide you treatment for your condition. Whether duloxetine once daily orally is tolerated and safe, in children (aged 7 through 11 years) and adolescents (aged 12 through 17 years)...
What is the current status of trial NCT00529789?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2007-08. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00529789?
The interventions under investigation include: duloxetine (DRUG).
Who is sponsoring clinical trial NCT00529789?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.